Oncomine Reporter Dx

Reporting software for precision oncology

The challenge of staying informed

Creating clear and concise oncology biomarker reports that contain accurate information in a timely manner is a formidable challenge. As the rate of biomarker-driven therapy approvals increases,[1] managing the targeted therapies for each type of cancer and updating this information from multiple sources becomes difficult and impractical. With up-to-date curated information from multiple public sources and customizable reporting, Ion Torrent™ Oncomine™ Reporter Dx software delivers the accuracy and flexibility to help improve patient care.

Connecting genomic alterations to evidence

Oncomine Reporter Dx is a turnkey reporting software solution that produces reports that are clear and fully customizable (Figure 1). Oncomine Reporter Dx links genomic variant information from Ion Torrent™ NGS results with relevant data contained in the Oncomine™ Knowledgebase. It is used to prepare a report that presents a patient sample–specific view of each biomarker matched to relevant evidence including approved therapies, guidelines, clinical trials, and peer reviewed literature (Figure 2).

To help ensure quality reporting, Oncomine Reporter Dx supports industry standard classification systems such as the joint consensus of AMP, ASCO, CAP, and ESCAT as well as customizable tiers.[2,3]



Example Clinical Lab

Example Clinical Lab System
123 Sample Avenue
City, Postal Code
Tel: +44 (123) 123-1234

Tracking Number: 00-123456789 | Case Number: 9876543-1 | Date: 11 May 2022 | 1 of 4

Date of Birth:	01 Aug 1965	**Primary Tumor Site:**	Lung
Sex:	Female	**Sample Type:**	FFPE
Smoking Status:	active smoker	**Sample ID:**	435678-FFPE-321
Case Number:	9876543-1	**Sample Collected:**	09 May 2022

Sample Cancer Type: Non-Small Cell Lung Cancer

Relevant Non-Small Cell Lung Cancer Findings

Gene	Finding	Gene	Finding
ALK	None detected	NTRK1	None detected
BRAF	None detected	NTRK2	None detected
EGFR	None detected	NTRK3	None detected
ERBB2	None detected	RET	***KIF5B-RET fusion***
KRAS	None detected	ROS1	None detected
MET	None detected		

Relevant Biomarkers

Tier	Genomic Alteration	Relevant Therapies (In this cancer type)	Relevant Therapies (In other cancer type)	Clinical Trials
I-A	*KIF5B-RET fusion*	**pralsetinib** [1,2] **selpercatinib** [1,2] cabozantinib	**pralsetinib** [2] **selpercatinib** [1,2]	10

Public data sources included in relevant therapies: EMA[1], ESMO, **FDA**[2], NCCN
Tier Reference: Mateo J, Chakravarty D, Dienstmann R et al. *A framework to rank genomic alterations as targets for cancer precision medicine: The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).* Annals of Oncology 2018; https://doi.org/10.1093/annonc/mdy263

Figure 1. Customizable report summarizing relevant clinical information in a single page or with optional details in additional pages.

Oncomine Knowledgebase

To keep pace with the latest insights, integration with the Oncomine Knowledgebase ensures that curated evidence leveraged by Oncomine Reporter Dx is updated monthly. Each piece of evidence within the Oncomine Knowledgebase is manually curated and standardized by independent reviewers for context, categorization, and concordance.

The Oncomine Knowledgebase ensures that data are comparable when there are differing formats from global sources. It provides global clinical trial information for more than 60 countries including contact information for enrollment. In addition, the curated Oncomine Knowledgebase contains more than 90 cancer types, including solid tumor, myeloid, and lymphoma subtypes.

Easy access to important information

Oncomine Reporter Dx provides an application programming interface (API) that facilitates integration with your laboratory information management system (LIMS) as well as efficient workflow automation in high-volume labs. Workflow templates enable streamlined access to a final report in three fast and easy steps: review, filter, and report.



Figure 2. Each biomarker will have annotations for relevant evidence related to labels for approved therapies, guidelines, clinical trials, and peer-reviewed literature within various cancer types.

Flexibility to meet your needs

The report builder enables you to select and order the report sections that you need. This flexibility lets you create a one-page summary or a multi-page detailed report. Additionally, you can choose from templates available in several languages, such as simplified and traditional Chinese, English, French, German, Italian, Japanese, Korean, Portuguese, and Spanish.

Ordering information

Product		Cat. No.
Oncomine Reporter Dx	One-year license	A54966

References

1. Mosele F., et al. (2020) Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. *Annals of Oncology 2020*, Volume 31-Issue 11.
2. Li et al. (2017) Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. *J Mol Diagn* 19(1):4–23.
3. Mateo et al. (2018) A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), *Ann Oncol* 2018 Sep 1;29(9):1895–1902.

Find out more at **oncomine.com/oncomine-reporter-dx**

For *In Vitro* Diagnostic Use. CE-IVD according to IVDD. Not available in all countries, including the United States.